Insulet (PODD) Downgraded to Sell at BidaskClub

BidaskClub lowered shares of Insulet (NASDAQ:PODD) from a hold rating to a sell rating in a research report report published on Thursday.

PODD has been the subject of several other reports. Jefferies Group raised their target price on Insulet from $58.00 to $67.00 and gave the company a buy rating in a research note on Friday, November 3rd. Canaccord Genuity upgraded Insulet from a hold rating to a buy rating and raised their target price for the company from $50.00 to $65.00 in a research note on Wednesday, November 1st. Raymond James Financial raised shares of Insulet from a market perform rating to an outperform rating and set a $80.00 price target on the stock in a research report on Monday, January 8th. Zacks Investment Research cut shares of Insulet from a buy rating to a hold rating in a research report on Saturday, November 11th. Finally, UBS Group raised shares of Insulet from a market perform rating to an outperform rating in a research report on Monday, January 8th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of Buy and an average price target of $62.53.

Shares of Insulet (PODD) traded up $2.29 on Thursday, hitting $75.18. The stock had a trading volume of 662,461 shares, compared to its average volume of 471,172. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88. The firm has a market cap of $4,241.31, a P/E ratio of -150.36 and a beta of 1.58. Insulet has a 12 month low of $38.43 and a 12 month high of $78.65.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.06. The company had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The firm’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period last year, the business posted ($0.05) EPS. equities research analysts predict that Insulet will post -0.43 earnings per share for the current fiscal year.

In other news, Director James C. Mullen bought 2,500 shares of the company’s stock in a transaction on Monday, November 13th. The shares were purchased at an average price of $67.45 per share, with a total value of $168,625.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 1.90% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of the business. Diversified Trust Co bought a new position in shares of Insulet during the 4th quarter worth approximately $218,000. Frontier Capital Management Co. LLC lifted its position in shares of Insulet by 42.4% during the 4th quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock worth $144,633,000 after buying an additional 624,465 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Insulet by 4.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 276,930 shares of the medical instruments supplier’s stock worth $19,109,000 after buying an additional 10,989 shares in the last quarter. KAMES CAPITAL plc lifted its position in shares of Insulet by 212.1% during the 4th quarter. KAMES CAPITAL plc now owns 237,324 shares of the medical instruments supplier’s stock worth $16,375,000 after buying an additional 161,290 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Insulet during the 3rd quarter worth approximately $1,414,000.

TRADEMARK VIOLATION WARNING: This piece of content was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/20/insulet-podd-downgraded-to-sell-at-bidaskclub.html.

Insulet Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply